Goodwin’s Intellectual Property team regularly works on the most important deals in the life sciences and biotech sector. Our close relationship with clients ensures that the best intellectual property strategies are in place to foster company and product growth and minimize risk. We take pride in structuring, negotiating, and executing complex license, collaboration and joint development agreements. Recently, our Cambridge team advised Renaissance Pharma Ltd., in its launch and exclusive license agreement with St. Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma patients globally – announced on August 01, 2023.
Manchester, UK-based Renaissance, is a rapidly emerging company focused on the development of life changing therapies in paediatric rare disease.
St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease, and other life-threatening disorders.
Goodwin partner, Malcolm Bates said: “We wish Renaissance and St. Jude every success in this very important agreement.”
Read the press release here.